Melanotan I
Melanocortin analog approved for erythropoietic protoporphyria.
What it is
Melanotan I (afamelanotide, brand name Scenesse) is a synthetic 13-amino-acid melanocortin receptor agonist with selectivity for MC1R. It was FDA-approved in 2019 for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP), a rare genetic disorder characterized by severe sun sensitivity.
Mechanism of action
Selective MC1R activation increases melanin production in melanocytes. The resulting skin darkening provides photoprotection in patients with EPP, reducing the painful phototoxic reactions characteristic of this condition. The selectivity for MC1R distinguishes afamelanotide from the broader-acting (and concerning) Melanotan II.
Approved indications
Prevention of phototoxicity in adults with erythropoietic protoporphyria. Administered as a subcutaneous implant approximately every two months.
Why this is out of scope at The Tide
Erythropoietic protoporphyria is a rare genetic disorder appropriately managed by hematology or specialized centers with experience in porphyria. Afamelanotide is administered through specialized hospital implant programs, not outpatient peptide clinics. The medication is not appropriate for cosmetic or general pigmentation purposes.
Where to learn more
The American Porphyria Foundation and specialized porphyria treatment centers are appropriate resources for patients with EPP.